Clinical Trials
19
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Gamida Cell ltd
- Target Recruit Count
- 13
- Registration Number
- NCT05296525
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸Dana-Farber/Mass General Brigham Cancer Care, Inc., Boston, Massachusetts, United States
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Gamida Cell ltd
- Target Recruit Count
- 36
- Registration Number
- NCT04260698
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Stanford University Cancer Institute, Palo Alto, California, United States
🇺🇸Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
- Conditions
- Hematological MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)LymphomaChronic Myelogenous Leukemia (CML)Acute Leukemia
- Interventions
- Other: Cord Blood Unit
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Gamida Cell ltd
- Target Recruit Count
- 125
- Registration Number
- NCT02730299
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸City of Hope, Los Angeles, California, United States
🇺🇸Stanford University Cancer Institute, Palo Alto, California, United States
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
- Conditions
- ThalassemiaSickle Cell Disease
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Gamida Cell ltd
- Target Recruit Count
- 1
- Registration Number
- NCT02504619
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Children's National, Washington, District of Columbia, United States
🇫🇷Hôpital Robert Debré, Paris, France
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
- Conditions
- Patients Transplanted With NiCord/CordIn (Omidubicel)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Gamida Cell ltd
- Target Recruit Count
- 33
- Registration Number
- NCT02039557
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next
News
FDA Grants Priority Review to Omidubicel for Severe Aplastic Anemia Treatment
The FDA has accepted Ayrmid Ltd.'s priority review application for omidubicel as a treatment for severe aplastic anemia, with a PDUFA target action date of December 10, 2025.